Cancer Clinical Trial -Elpiscience Biopharma-ES002023-1001

A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

Drug

ES002023

Phase

Phase I

Condition

Advanced Solid Tumors, Colorectal Adenocarcinoma, Non-Small Cell Lung, Pancreatic

Keywords

ENTPD1 (-)